Products Categories
CAS No.: | 59467-70-8 |
---|---|
Name: | Midazolam |
Article Data: | 20 |
Molecular Structure: | |
Formula: | C18H13 Cl F N3 |
Molecular Weight: | 325.773 |
Synonyms: | Dormicum;Midanium;Midosed;Midazolamum [INN-Latin];DEA No. 2884;[15N]-Midazolam;Dazolam;Midazolamum;[14C]-Midazolam;Versed; |
EINECS: | 261-774-5 |
Density: | 1.35 g/cm3 |
Melting Point: | > 290ºC |
Boiling Point: | 496.9 °C at 760 mmHg |
Flash Point: | 254.3 °C |
Solubility: | insoluble in water |
Appearance: | white crystallized powder |
Hazard Symbols: | F,T |
Risk Codes: | 11-23/24/25-39/23/24/25 |
Safety: | Poison by intravenous route. Moderately toxic by ingestion. When heated to decomposition it emits toxic fumes of F−, Cl−, and NOx. |
PSA: | 104.78000 |
LogP: | 3.47160 |
The Midazolam, with the CAS registry number 59467-70-8, is also known as 8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine. It belongs to the product categories of Intermediates & Fine Chemicals; Pharmaceuticals; Aromatics; Heterocycles. This chemical's molecular formula is C18H13ClFN3 and molecular weight is 325.77. What's more,Its systematic name is Midazolam.It is a White Crystaline Solid.And it is a short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
Physical properties about Midazolam are:
(1)ACD/LogP: 3.798; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): 3.23; (4)ACD/LogD (pH 7.4): 3.78; (5)ACD/BCF (pH 5.5): 123.20; (6)ACD/BCF (pH 7.4): 438.42; (7)ACD/KOC (pH 5.5): 753.79; (8)ACD/KOC (pH 7.4): 2682.51; (9)#H bond acceptors: 3; (10)#H bond donors: 0; (11)#Freely Rotating Bonds: 1; (12)Index of Refraction: 1.671; (13)Molar Refractivity: 89.654 cm3; (14)Molar Volume: 239.845 cm3; (15)Surface Tension: 46.1990013122559 dyne/cm; (16)Density: 1.358 g/cm3; (17)Flash Point: 254.295 °C; (18)Enthalpy of Vaporization: 76.472 kJ/mol; (19)Boiling Point: 496.865 °C at 760 mmHg; (20)Vapour Pressure: 0 mmHg at 25°C.
You can still convert the following datas into molecular structure:
(1)SMILES:Fc4ccccc4C/1=N/Cc3cnc(n3c2c\1cc(Cl)cc2)C;
(2)Std. InChI:InChI=1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3;
(3)Std. InChIKey:DDLIGBOFAVUZHB-UHFFFAOYSA-N.
The toxicity data of Midazolam as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
child | TDLo | oral | 500ug/kg (.5mg/kg) | BEHAVIORAL: EXCITEMENT | Annals of Emergency Medicine. Vol. 24, Pg. 1173, 1994. |
mouse | LD50 | intramuscular | > 50mg/kg (50mg/kg) | LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 13(Suppl, |
mouse | LD50 | intravenous | 50mg/kg (50mg/kg) | British Journal of Clinical Pharmacology. Vol. 16, Pg. 37S, 1983. | |
mouse | LDLo | oral | 500mg/kg (500mg/kg) | SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE BEHAVIORAL: ATAXIA BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 13(Suppl, |
rat | LD50 | intramuscular | > 50mg/kg (50mg/kg) | LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 13(Suppl, |
rat | LD50 | intravenous | 75mg/kg (75mg/kg) | British Journal of Clinical Pharmacology. Vol. 16, Pg. 37S, 1983. | |
rat | LD50 | oral | 215mg/kg (215mg/kg) | LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION BEHAVIORAL: ATAXIA BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 13(Suppl, |
women | TDLo | intravenous | 74ug/kg/1M-C (.074mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Australian and New Zealand Journal of Medicine. Vol. 25, Pg. 743, 1995. |